NASDAQ:CHMAChiasma Stock Price, Forecast & News

Chiasma's stock was trading at $3.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHMA stock has increased by 10.2% and is now trading at $4.32. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chiasma.

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chiasma.

Chiasma Inc (NASDAQ:CHMA) announced its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.05. View Chiasma's earnings history.

5 analysts have issued 12-month target prices for Chiasma's stock. Their forecasts range from $11.00 to $19.00. On average, they anticipate Chiasma's share price to reach $14.75 in the next twelve months. This suggests a possible upside of 241.4% from the stock's current price. View analysts' price targets for Chiasma.

Press coverage about CHMA stock has trended neutral recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Chiasma earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Chiasma.

Some companies that are related to Chiasma include ImmunoGen (IMGN), Omeros (OMER), Legend Biotech (AMTI), Frequency Therapeutics (FREQ), Homology Medicines (FIXX), ZIOPHARM Oncology (ZIOP), Applied Therapeutics (APLT), Kadmon (KDMN), Passage Bio (ORIC), Provention Bio (PRVB), Aprea Therapeutics (APRE), Eagle Pharmaceuticals (EGRX), RAPT Therapeutics (RAPT), Cue Biopharma (CUE) and Passage Bio (KROS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX), Alnylam Pharmaceuticals (ALNY), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Progenics Pharmaceuticals (PGNX).

(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.32.

Chiasma has a market capitalization of $182.56 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]